Evidence map›Paper›PMID 33448017›Full record

ArticleThe Journal of pathology2021

More than acinar identity? A novel cystic phenotype suggests broader roles for NR5A2 in pancreatic cancer

Katherine J Aney, Sahar Nissim

Open access · greenAbstract readComment
In one paragraph

Article in The Journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Katherine J AneyHarvard-MIT Health Sciences and Technology, Harvard Medical School, Boston, MA, USA.
Sahar NissimHarvard-MIT Health Sciences and Technology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-2303-6415
Brigham and Women's Hospital · USHarvard University · US

Funding

Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
STRUCTURE-FUNCTION RELATIONSHIPS IN THE ALIMENTARY TRACTP30DK034854 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI LYNN BRY · 1986 to 2026
$32.4M
The Role of NR5A2 in Pancreas Development and DiseaseK08DK105326 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI NISSIM, SAHAR · 2015 to 2019
$828k
The Impacts of NR5A2 Pharmacologic Agonism on Pancreas Development and DiseaseR03DK122232 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI NISSIM, SAHAR · 2019 to 2020
$179k
NIDDK NIH HHS K08 DK105326NIDDK NIH HHS P30 DK034854NIDDK NIH HHS R03 DK122232NIGMS NIH HHS T32 GM007753
6 · The paper itself

Abstract

The prognosis for pancreatic ductal adenocarcinoma (PDAC) remains dismal. Multiple genome-wide association studies (GWAS) have implicated the nuclear receptor NR5A2 in modulating PDAC risk, but mechanisms for this association are not understood. NR5A2 is a transcription factor that maintains acinar cell identity, and heterozygous loss of Nr5a2 in mice accelerates oncogenic Kras-driven formation of pancreatic intraepithelial neoplasia (PanIN), a PDAC precursor derived from acinar cells. In a recent issue of The Journal of Pathology, Cobo et al characterize a novel mouse model that uses Ptf1a:Cre to drive oncogenic Kras as well as heterozygous Nr5a2 inactivation. In addition to the expected PanIN lesions, these mice exhibited a surprising phenotype: large pancreatic cystic lesions which have not been previously reported. Comparing expression of oncogenic Kras and heterozygous Nr5a2 in various mouse models reveals several possible explanations for these cystic lesions. Importantly, these differences across mouse models suggest that NR5A2 may contribute to PDAC precursors in ways beyond its previously characterized acinar cell-autonomous role. These observations highlight that pathways implicated by GWAS may have roles in unexpected cell types, and an understanding of these roles will be critical to guide new preventive and treatment strategies for PDAC. © 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAcinar CellsAnimalsGenome-Wide Association StudyMicePhenotypeReceptors, Cytoplasmic and NuclearNr5a2 protein, mouseReceptors, Cytoplasmic and Nuclearcystic lesionsNR5A2pancreatic cancerPanIN

Identifiers

PMID33448017
PMCPMC8439571
OpenAlexW3121247185

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.